Get Started

RCKT

NASD Rocket Pharmaceuticals, Inc.
Oct 25, 2026 · 7:54 PM ET EOD Market Closed

$2.29 ↑ +0.00 (+0.00%) Trading Up from the previous close of $2.29, and at the day’s high of $2.29

YTD change
-34.76%
vs 20-day SMA
-6.55%
vs 200-day SMA
-34.43%

Price ranges

Previous day
$2.17 $2.29
open $2.27 close $2.29
+$0.02 (+0.88%)
Today
$2.17 $2.29
$2.29
Past week
$2.17 $2.39
from $2.36 now $2.29
-$0.07 (-2.97%)
Past month
$2.17 $2.80
from $2.69 now $2.29
-$0.40 (-14.87%)
This year
$2.17 $5.45
from $3.51 now $2.29
-$1.22 (-34.76%)

Price & Performance

-1.20 (-34.38%) / 6M

$2.02$2.81$3.61$4.40Apr 27Jul 27Oct 23

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Not So Good
  • The stock is 96.6% away from all-time highs of $67.48
  • RCKT is down 35% since the beginning of the year
  • RCKT is down 39% over the past 12 months
  • RCKT is down 15% over the past 1 month
  • 15% of all RCKT investors are betting against RCKT

RCKT reads not so good: price sits below both the 20- and 200-day averages, the 12-month move is -41.9%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable Yes
EPS $1.08
Earnings momentum +373.4% Quarterly EPS growth
Quarterly change +373.4%

Valuation

P/E ratio N/A
Enterprise value $5.6M
Beta 1.03

Balance sheet & scale

IncomeN/A
RevenueN/A
Cash$283.7M
Debt$24.8K
Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD
Sector Professional, Scientific, and Technical Services
Industry Group Scientific Research and Development Services
Market cap $251.4M

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. The firm's multi-platform development approach applies the lentiviral vector and adeno-associated viral vector gene therapy platforms. Its clinical program is an LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded on July 7, 1999 and is headquartered in Cranbury, NJ.

Competitor comparison

TickerCompany PriceChange
AMGN Amgen Inc. $439.26 -1.79%
MRNA Moderna, Inc. $200.10 -1.25%
RVMD Revolution Medicines, Inc. $186.99 -0.37%
ROIV Roivant Sciences Ltd. $36.49 -2.56%
BNTX BioNTech SE Sponsored ADR $88.12 -1.73%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.